XM اپنی سروسز امریکہ کے شہریوں کو فراہم نہیں کرتا ہے۔
R
R

Regeneron


خبر

Regeneron loses key defense in 19 treatment patent lawsuit

Regeneron loses key defense in COVID-19 treatment patent lawsuit By Blake Brittain Oct 4 - Biotech company Regeneron Pharmaceuticals REGN.O lost a bid on Friday to be held immune from allegations that it misused a patented protein while testing a COVID-19 treatment. U.S. District Judge Philip Halpern rejected Regeneron's pretrial argument that he should throw out Allele Biotechnology and Pharmaceuticals' patent lawsuit over the treatment based on a federal law allowing the use of patented invent
P
R

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Constellation Energy Corp CEG.OQ +3.9% Diamondback Energy Inc FANG.OQ +3.7% NVIDIA Corp NVDA.OQ +3.0% Paccar Inc PCAR.OQ +2.8% Trade Desk Inc TTD.OQ +2.2% Bottom Performers Percent Change Tesla Inc TSLA.OQ -3.9% Warner Bros Discovery Inc WBD.OQ -3.5% Take-Two Interactive Software Inc TTWO.OQ -2.9% Moderna Inc MRNA.OQ -2.8% Regeneron Pharmaceuticals Inc REGN.OQ -2.8% The Nasdaq 100
N
P
R
T
T
U
D
T

U.S. stocks weekly: Streaking in September

RPT-BUZZ-U.S. stocks weekly: Streaking in September Repeats from Friday with no changes to text. Updates chart ** S&P 500 .SPX extends winning streak to three weeks, adds 0.6% amid tame inflation data and China stimulus boost .N ** SPX on pace for monthly gain, take that September! ** Dow .DJI and Nasdaq .IXIC also up three consecutive weeks, though the latter still lined up at the velvet rope ** This as benchmark Treasury yield perks up , but can't hold 3-week highs after PCE ** Most sectors fl
A
C
M
R
V
L
W
U
U

U.S. stocks weekly: Streaking in September

BUZZ-U.S. stocks weekly: Streaking in September ** S&P 500 .SPX extends winning streak to three weeks, adds 0.6% amid tame inflation data and China stimulus boost .N ** SPX on pace for monthly gain, take that September! ** Dow .DJI and Nasdaq .IXIC also up three consecutive weeks, though the latter still lined up at the velvet rope ** This as benchmark Treasury yield perks up , but can't hold 3-week highs after PCE ** Most sectors fleet of foot: Materials sprint to front of the pack, while Energ
A
C
M
R
V
L
W
U
U

U.S. STOCKS IonQ, Cassava Sciences, MeridianLink

BUZZ-U.S. STOCKS ON THE MOVE-IonQ, Cassava Sciences, MeridianLink Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The blue-chip Dow rose on Friday to hit an intraday record and small-cap stocks outperformed after a benign inflation report cleared the way for the Federal Reserve to focus on shoring up the labor market while continuing its interest rate easing.
C
E
R
S
R
W
U
U
G
C
L

U.S. STOCKS Regeneron, HP Inc, Honeywell International

BUZZ-U.S. STOCKS ON THE MOVE-Regeneron, HP Inc, Honeywell International Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The blue-chip Dow rose on Friday to hit an intraday record high and small-cap stocks outperformed after a benign inflation report cleared the way for the Federal Reserve to focus on shoring up the labor market while continuing its interest rate easing.
A
C
E
L
R
S
W
W
U
U
D
C
L

Regeneron rises as US FDA approves Dupixent for 'smoker's lung'

BUZZ-Regeneron rises as US FDA approves Dupixent for 'smoker's lung' ** Shares of Regeneron Pharmaceuticals REGN.O rise 1.6% to $1,056.92 in early trading ** Co and French partner Sanofi SASY.PA say the U.S. FDA has approved their blockbuster drug, Dupixent, for patients with a chronic lung disease commonly known as "smoker's lung" ** Dupixent is t
R
S

Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'

UPDATE 2-Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung' Adds details on Dupixent in paragraphs 2 and 4, analyst estimates in paragraph 5, trial details in paragraph 8 By Sriparna Roy Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi SASY.PA and Regeneron's REGN.O blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
R
S

Dupixent approved in United States as first-ever biologic medicine for patients with COPD

BRIEF-Dupixent approved in United States as first-ever biologic medicine for patients with COPD Sept 27 (Reuters) - Sanofi SA SASY.PA /REGENERON REGN.O : PRESS RELEASE: DUPIXENT APPROVED IN THE US AS THE FIRST-EVER BIOLOGIC MEDICINE FOR PATIENTS WITH COPD PRESS RELEASE: DUPIXENT APPROVED IN THE US AS THE FIRST-EVER BIOLOGIC MEDICINE FOR PATIENTS WI
R
S

US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'

US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung' Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi SASY.PA and Regeneron's REGN.O blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies said on Friday. Reporting by Sriparna Roy in Bengaluru; Editi
R
S

What to Watch in the Day Ahead - Friday, September 27

What to Watch in the Day Ahead - Friday, September 27 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Federal Reserve Board Governor Michelle Bowman is set to participate in a conversation before the Alabama Bankers Association Bank CEO Meeting in Birmingham, Alabama.
B
R
S

Amgen falls after reporting mixed data on two drugs

BUZZ-Amgen falls after reporting mixed data on two drugs ** Shares of Amgen AMGN.O fall as much as 4.4% to a near two-month low of $316.22 ** Stock is set for its worst day in nearly two months if losses hold ** Late on Tuesday drugmaker said its drugs Uplizna and rocatinlimab, for a rare muscular disorder and a skin disease, respectively, met the
A
R
S

Amgen's muscular disorder drug meets main goal in late-stage study

UPDATE 4-Amgen's muscular disorder drug meets main goal in late-stage study Amgen's Uplizna succeeds in study for muscle-weakening Analysts say data from another experimental drug not 'competitive' Shares fall 2% in extended trading on mixed datasets Adds analyst comments in paragraphs 4, 10 and 11, trial data in paragraph 3, 8 and 9, exec comment in paragraph 6 By Bhanvi Satija and Puyaan Singh Sept 24 (Reuters) - Amgen AMGN.O said on Tuesday that its drug helped improve daily activities includ
A
A
R
S

Regeneron falls after Leerink Partners downgrades to 'market perform', cuts PT

BUZZ-Regeneron falls after Leerink Partners downgrades to 'market perform', cuts PT Updates * * Shares of drugmaker Regeneron REGN.O fall 4.09% to $1,047.29 ** Brokerage Leerink Partners downgrades co to "market perform" from "outperform," cuts PT to $1,077 from $1,175 ** Says trigger for the downgrade was a court ruling for co's 2 milligram dose version of eye-care drug Eylea ** On Monday, a federal judge in West Virginia said REGN cannot immediately block U.S.
A
R

Amgen gets early win in Regeneron lawsuit over Eylea biosimilar

UPDATE 1-Amgen gets early win in Regeneron lawsuit over Eylea biosimilar Adds reponse from Regeneron to Sept 23 story in paragraph 4, corrects company locations in paragraphs 8 and 9 By Blake Brittain Sept 23 (Reuters) - Regeneron REGN.O cannot immediately block U.S. sales of rival Amgen's AMGN.O proposed copy of its blockbuster eye-care drug Eylea, a federal judge in West Virginia said on Monday.
A
R

Amgen gets early win in Regeneron lawsuit over Eylea biosimilar

UPDATE 1-Amgen gets early win in Regeneron lawsuit over Eylea biosimilar Adds reponse from Regeneron to Sept 23 story in paragraph 4, corrects company locations in paragraphs 8 and 9 By Blake Brittain Sept 23 (Reuters) - Regeneron REGN.O cannot immediately block U.S. sales of rival Amgen's AMGN.O proposed copy of its blockbuster eye-care drug Eylea, a federal judge in West Virginia said on Monday.
A
R

U.S. STOCKS Copper miners, Biogen, Salesforce

BUZZ-U.S. STOCKS ON THE MOVE-Copper miners, Biogen, Salesforce Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were set for a subdued open on Tuesday, as investors scoured for clues on what the Federal Reserve's next policy move might be, while commodity stocks got a boost after China unveiled a bumper stimulus package.
A
B
C
M
N
R
S
S
V
L
R
W
U

U.S. Costco Wholesale, McKesson, Starbucks

CORRECTED-U.S. RESEARCH ROUNDUP-Costco Wholesale, McKesson, Starbucks Corrects named item code to RCH/US from RCH/EUROPE, the same error was there in a previous version of the U.S. research roundup Sept 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Costco Wholesale, McKesson and Starbucks, on Tuesday.
C
R
S
M
C
L

U.S. STOCKS Copper miners, Biogen, Salesforce

BUZZ-U.S. STOCKS ON THE MOVE-Copper miners, Biogen, Salesforce Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures were muted in choppy trading on Tuesday, as investors scoured for clues on what the Federal Reserve's next policy move might be, while mining stocks got a boost after China unveiled a bumper stimulus package.
A
B
C
N
R
S
V
R
U

Leerink Partners downgrades Regeneron to 'market perform', cuts PT

BUZZ-Leerink Partners downgrades Regeneron to 'market perform', cuts PT ** Brokerage Leerink Partners downgrades Regeneron REGN.O to "market perform" from "outperform," cuts PT to $1,077 from $1,175 ** Says trigger for the downgrade was a court ruling for co's 2 milligram dose version of eye-care drug Eylea ** On Monday, a federal judge in West Virginia said REGN cannot immediately block U.S.
A
R



شرائط

مشہور اثاثے

دستبرداری: XM Group کے ادارے ہماری آن لائن تجارت کی سہولت تک صرف عملدرآمد کی خدمت اور رسائی مہیا کرتے ہیں، کسی شخص کو ویب سائٹ پر یا اس کے ذریعے دستیاب کانٹینٹ کو دیکھنے اور/یا استعمال کرنے کی اجازت دیتا ہے، اس پر تبدیل یا توسیع کا ارادہ نہیں ہے ، اور نہ ہی یہ تبدیل ہوتا ہے یا اس پر وسعت کریں۔ اس طرح کی رسائی اور استعمال ہمیشہ مشروط ہوتا ہے: (i) شرائط و ضوابط؛ (ii) خطرہ انتباہات؛ اور (iii) مکمل دستبرداری۔ لہذا اس طرح کے مواد کو عام معلومات سے زیادہ کے طور پر فراہم کیا جاتا ہے۔ خاص طور پر، براہ کرم آگاہ رہیں کہ ہماری آن لائن تجارت کی سہولت کے مندرجات نہ تو کوئی درخواست ہے، اور نہ ہی فنانشل مارکیٹ میں کوئی لین دین داخل کرنے کی پیش کش ہے۔ کسی بھی فنانشل مارکیٹ میں تجارت میں آپ کے سرمائے کے لئے ایک خاص سطح کا خطرہ ہوتا ہے۔

ہماری آن لائن تجارتی سہولت پر شائع ہونے والے تمام مٹیریل کا مقصد صرف تعلیمی/معلوماتی مقاصد کے لئے ہے، اور اس میں شامل نہیں ہے — اور نہ ہی اسے فنانشل، سرمایہ کاری ٹیکس یا تجارتی مشورے اور سفارشات؛ یا ہماری تجارتی قیمتوں کا ریکارڈ؛ یا کسی بھی فنانشل انسٹرومنٹ میں لین دین کی پیشکش؛ یا اسکے لئے مانگ؛ یا غیر متنازعہ مالی تشہیرات پر مشتمل سمجھا جانا چاہئے۔

کوئی تھرڈ پارٹی کانٹینٹ، نیز XM کے ذریعہ تیار کردہ کانٹینٹ، جیسے: راۓ، خبریں، تحقیق، تجزیہ، قیمتیں اور دیگر معلومات یا اس ویب سائٹ پر مشتمل تھرڈ پارٹی کے سائٹس کے لنکس کو "جیسے ہے" کی بنیاد پر فراہم کیا جاتا ہے، عام مارکیٹ کی تفسیر کے طور پر، اور سرمایہ کاری کے مشورے کو تشکیل نہ دیں۔ اس حد تک کہ کسی بھی کانٹینٹ کو سرمایہ کاری کی تحقیقات کے طور پر سمجھا جاتا ہے، آپ کو نوٹ کرنا اور قبول کرنا ہوگا کہ یہ کانٹینٹ سرمایہ کاری کی تحقیق کی آزادی کو فروغ دینے کے لئے ڈیزائن کردہ قانونی تقاضوں کے مطابق نہیں ہے اور تیار نہیں کیا گیا ہے، اسی طرح، اس پر غور کیا جائے گا بطور متعلقہ قوانین اور ضوابط کے تحت مارکیٹنگ مواصلات۔ براہ کرم یقینی بنائیں کہ آپ غیر آزاد سرمایہ کاری سے متعلق ہماری اطلاع کو پڑھ اور سمجھ چکے ہیں۔ مذکورہ بالا معلومات کے بارے میں تحقیق اور رسک وارننگ ، جس تک رسائی یہاں حاصل کی جا سکتی ہے۔

خطرے کی انتباہ: آپکا سرمایہ خطرے پر ہے۔ ہو سکتا ہے کہ لیورج پروڈکٹ سب کیلیے موزوں نہ ہوں۔ براہ کرم ہمارے مکمل رسک ڈسکلوژر کو پڑھیے۔